Iris Acosta Amezquita
Primary Care · Newark, NJNPI 1295482610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.
Across 153 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$422
- GSK$393
- Lilly USA, LLC$369
- Bayer$335
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$303
- Madrigal Pharmaceuticals$233
- plus $657 from 11 others
What the payments were for
- Food & beverage$2,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $422 |
| GSK | 21 | $393 |
| Lilly USA, LLC | 26 | $369 |
| Bayer | 18 | $335 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $303 |
| Madrigal Pharmaceuticals | 2 | $233 |
| Boehringer Ingelheim | 10 | $158 |
| Pfizer | 6 | $95 |
| Novo Nordisk | 5 | $94 |
| Amgen | 5 | $73 |
| Merck | 4 | $60 |
| AstraZeneca | 2 | $47 |
| AbbVie | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Ardelyx, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,711 in reported general payments places this provider in the 85th percentile of 330 primary care providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 168 | $119,078 |
| JardianceEmpagliflozin | 111 | $110,762 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 154 | $107,999 |
| OzempicSemaglutide | 103 | $105,950 |
| KerendiaFinerenone | 143 | $105,677 |
| EliquisApixaban | 105 | $87,347 |
| TrulicityDulaglutide | 75 | $85,943 |
| MounjaroTirzepatide | 65 | $74,753 |
| FarxigaDapagliflozin Propanediol | 92 | $74,365 |
| JanuviaSitagliptin Phosphate | 59 | $47,407 |
| TradjentaLinagliptin | 39 | $33,970 |
| EntrestoSacubitril/Valsartan | 43 | $28,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $24,264 |
| ProliaDenosumab | 13 | $22,893 |
| Levocarnitine | 208 | $22,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Glyxambi, Synjardy | $158 | $186,265198 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $369 | $160,697140 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy | $393 | $129,094216 claims |
| Novo NordiskOzempic, Rybelsus | $94 | $124,875122 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $47 | $107,185155 claims |
| BayerKerendia | $335 | $105,677143 claims |
| PfizerEliquis | $95 | $87,347105 claims |
| MerckJanuvia, Janumet Xr | $60 | $59,17571 claims |
| NovartisEntresto | $422 | $28,90443 claims |
| AmgenProlia | $73 | $22,89313 claims |
| AbbVieLinzess | $46 | $17,17926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 330 primary care providers in New Jersey.
Other primary care in Newark
- Shazam BacchusNewark$7K
- Tameka VillaNewark$5K
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.